<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042792</url>
  </required_header>
  <id_info>
    <org_study_id>2019-00916; ks18Pfister2</org_study_id>
    <nct_id>NCT04042792</nct_id>
  </id_info>
  <brief_title>Characterization of Adalimumab Concentrations in Pediatric Patients With Inflammatory Rheumatic Disease With and Without Methotrexate</brief_title>
  <acronym>ADA in PiRD</acronym>
  <official_title>Characterization of Adalimumab Concentrations in Pediatric Patients With Inflammatory Rheumatic Disease With and Without Methotrexate (ADA in PiRD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess standardized Adalimumab (ADA) concentrations in Pediatric&#xD;
      inflammatory rheumatic diseases (PiRD) patients treated with ADA for ≥ 12 weeks with and&#xD;
      without concomitant methotrexate (MTX) therapy and to assess peak and trough ADA&#xD;
      concentrations in ADA naïve patients after first ADA administration with and without MTX&#xD;
      (pre-phase).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 26, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ADA concentration (in mg/L)</measure>
    <time_frame>at study inclusion</time_frame>
    <description>ADA concentration (in mg/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADA concentration (in mg/L)</measure>
    <time_frame>during regular clinical follow up 3-6 months after inclusion</time_frame>
    <description>ADA concentration (in mg/L)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">28</enrollment>
  <condition>Rheumatic Diseases</condition>
  <arm_group>
    <arm_group_label>ADA for ≥12 weeks and concomitant MTX therapy</arm_group_label>
    <description>PiRD patients with ADA for ≥12 weeks and concomitant MTX therapy (oral or subcutaneous)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADA for ≥ 12 weeks without MTX</arm_group_label>
    <description>PiRD patients with ADA for ≥ 12 weeks without MTX ≥ 12 weeks (or never exposed to MTX)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacokinetics (PK) measurement</intervention_name>
    <description>two ADA-PK samples will be collected during routine rheumatology visits in case of medical indicated blood draw (1 trough PK sample and 1 random PK sample per subject)</description>
    <arm_group_label>ADA for ≥ 12 weeks without MTX</arm_group_label>
    <arm_group_label>ADA for ≥12 weeks and concomitant MTX therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        PiRD patients treated with ADA for medical reasons at the University Children's Hospital&#xD;
        Basel/ Switzerland and at the University Children's Hospital of Tuebingen/ Germany&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of a juvenile idiopathic Arthritis (JIA), uveitis or chronic&#xD;
             recurrent multifocal osteomyelitis (CRMO)&#xD;
&#xD;
          -  Medical indication for initiation of ADA treatment or established ADA therapy for ≥ 12&#xD;
             weeks&#xD;
&#xD;
          -  Exclusion of chronic infections&#xD;
&#xD;
          -  No parallel treatment with other biologic medications&#xD;
&#xD;
          -  Available patient history since ADA start&#xD;
&#xD;
          -  No pregnancy&#xD;
&#xD;
          -  Ability to comply with the entire study protocol&#xD;
&#xD;
          -  Willingness to participate with signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other rheumatic inflammatory diseases&#xD;
&#xD;
          -  Age &lt; 2 years or &gt;18 years&#xD;
&#xD;
          -  PiRD patients and parents with cognitive impairments preventing to understand study&#xD;
             requirements&#xD;
&#xD;
          -  Additional severe chronic disease (kidney failure, liver insufficiency), malignancies&#xD;
             or prior chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Pfister, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital Basel (UKBB), University of Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Children's Hospital Tubingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Basel Children's Hospital</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>methotrexate</keyword>
  <keyword>drug-drug interaction</keyword>
  <keyword>trough ADA concentration</keyword>
  <keyword>peak ADA concentration</keyword>
  <keyword>Pediatric inflammatory rheumatic diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

